NCT00609947已完成不适用
A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
Medtronic Vascular2 个研究点 分布在 1 个国家目标入组 241 人开始时间: 2008年1月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 241
- 试验地点
- 2
- 主要终点
- Major Adverse Cardiac Events (MACE) Rate
研究概览
简要总结
The objective of this study is to verify the safety and efficacy of the Endeavor Zotarolimus-Eluting Coronary Stent System for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤27 mm in native coronary arteries with reference vessels ≥ 2.25 mm to ≤ 2.75 mm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •GENERAL INCLUSION CRITERIA:
- •The patient is ≥18 years of age.
- •The patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or positive functional study.
- •The patient is an acceptable candidate for Percutaneous Transluminal Coronary Angiography (PTCA), stenting, and emergent Coronary Artery Bypass Grafting (CABG) surgery.
- •Female patients of childbearing potential must have a negative pregnancy test within 7 days before the procedure.
- •The patient or patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board of the respective clinical site.
- •The patient agrees to return to same research facility for all required post-procedure follow-up visits.
- •ANGIOGRAPHIC INCLUSION CRITERIA
- •1. The target lesion/vessel must meet the following criteria:
- •The patient requires treatment of either:
- •A single de novo lesion located in a native coronary artery amenable to treatment with a 2.25mm, 2.5mm or 2.75mm stent, or
- •Two de novo lesions located in separate target vessels, with at least one of the target lesions amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent and the second lesion amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent or a 3.0mm or 3.5mm approved Endeavor stent.
- •The lesion(s) must be ≤ 27mm in length.
- •The lesion(s) must have a stenosis of ≥ 50% and < 100%.
- •The vessel(s) has (have) a thrombolysis in myocardial infarction (TIMI) flow 2 or greater.
- •The target vessel reference diameter must be ≥ 2.25mm and ≤ 2.75mm and the second target vessel reference diameter, if present, must be ≥ 2.25mm and ≤ 3.5mm.
- •All target lesions can be treated with a Medtronic Endeavor stent.
排除标准
- •Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticlopidine, clopidogrel, cobalt, nickel, chromium, molybdenum, polymer coatings, or sensitivity to contrast media, which cannot be adequately pre-medicated
- •History of allergic reaction or significant sensitivity to drugs such as zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative
- •Platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or white blood cell count <3,000 cells/mm³
- •Serum creatinine level >2.0 mg/dl within 7 days prior to index procedure
- •Evidence of acute MI within 72 hours of intended index procedure
- •Planned PCI of any vessel within 30 days pre or post-index procedure and/or planned PCI of the target vessel(s) within 12 months post-procedure.
- •During the index procedure, the target lesion(s) requires treatment with a device other than PTCA prior to stent placement
- •History of stroke or transient ischemic attack (TIA) within prior 6 months
- •Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months.
- •History of bleeding diathesis or coagulopathy or patient will refuse blood transfusions.
- •Concurrent medical condition with life expectancy of less than 12 months.
- •Any previous or planned treatment of target vessel with anti-restenotic therapies including but not limited to brachytherapy.
- •Currently participating in an investigational drug or another device study that has not completed primary endpoint or that clinically interferes with current study endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures.
- •Documented left ventricular ejection fraction (LVEF) <30% at most recent evaluation.
- •Inability to comply with protocol required medication regimen ANGIOGRAPHIC EXCLUSION CRITERIA
- •1. Target lesion(s) located in native vessel distal to anastomosis with saphenous vein graft or a left/right internal mammary artery bypass with >40% diameter stenosis anywhere within graft.
- •2. Previous stenting in the target vessel(s) unless the following conditions are met:
- •a. It has been at least 9 months since the previous stenting, and b. The target lesion(s) is/are at least 15mm away from the previously placed stent.
- •3. Target vessel has other lesions with >40% diameter stenosis based on visual estimate or on-line QCA
- •Target vessel(s) has/have evidence of thrombus
- •Target vessel(s) is excessively tortuous (two bends ≥90º to reach target lesion)
- •Target lesion has any of the following characteristics:
- •Location is aorto-ostial, an unprotected left main lesion, or within 5 mm of the origin of the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA)
- •Involves a side branch >2.0 mm in diameter
- •Is at or distal to a >45º bend in the vessel
- •Is severely calcified
- •Involves a bifurcation
- •Unprotected left main coronary artery disease
研究组 & 干预措施
Endeavor Zotarolimus-Eluting Coronary Stent
Experimental
Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
干预措施: Endeavor Zotarolimus-Eluting Coronary Stent (Device)
结局指标
主要结局
Major Adverse Cardiac Events (MACE) Rate
时间窗: 12 months post-procedure
Major Adverse Cardiac Events rate at 12 months post-procedure defined as death, target-vessel Myocardial Infarction (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization, repeat percutaneous transluminal coronary angioplasty or cardiac bypass surgery.
In-segment Percent Diameter Stenosis at 8 Months Post-procedure
时间窗: 8 months post-procedure
In-segment percent diameter stenosis at 8 months post-procedure with percent diameter stenosis defined as the value calculated as 100 x (RVD - Minimal Lumen Diameter (MLD)/RVD using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiography (QCA).
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Medtronic RESOLUTE US Clinical TrialCoronary Artery DiseaseNCT00726453Medtronic Vascular1,516
已完成
不适用
Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical StudyCoronary Artery DiseaseNCT02419521Medtronic Vascular75
已完成
不适用
Medtronic Resolute Onyx 2.0 mm Clinical StudyCoronary Artery DiseaseNCT02412501Medtronic Vascular101
已完成
1 期
The Medtronic RESOLUTE Clinical TrialCoronary Artery DiseaseNCT00248079Medtronic Vascular139
已完成
4 期
Clinical Performance of the Endeavor Zotarolimus-Eluting Stent in Real-world Japanese Patients: A Prospective Multicenter RegistryIschemic Heart Disease/Coronary Artery DiseaseJPRN-UMIN000008076Associations for Establishment of Evidence in Interventions1,000